Saxenda vs Rybelsus: Cost and Access Head-to-Head

HealthRX.com

Rybelsus is a diabetes drug, so coverage differs

Print or save as PDF

Key numbers

  • 11%Share of 136 marketplace plans in 34 states with any coverage for the obesity drugs examined, per a 2018 analysisSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 4%Weight loss below this share of baseline body weight by the Saxenda checkpoint means the label says to stopSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 3 mg daily for 30 daysRybelsus starting dose in the label, which the label states is not effective for blood sugar controlSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

Medicaid prescriptions: Saxenda and Rybelsus

State Medicaid programmes paid for 28,807 Saxenda prescriptions and 200,179 Rybelsus prescriptions in 2025, with $34.2M and $256.7M reimbursed before rebates. Figures cover these two brands only.

Medicaid prescriptions: Saxenda and Rybelsus: the figures
MeasureValue
Saxenda: prescriptions, 202528,807
Rybelsus: prescriptions, 2025200,179
Saxenda: reimbursed before rebates$34.2M
Rybelsus: reimbursed before rebates$256.7M
Saxenda: states and territories reporting15
Rybelsus: states and territories reporting51

Source: CMS, Medicaid State Drug Utilization Data 2025, data as of 2025

How this was calculated

Matched Medicaid product codes to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products for each side and summed prescriptions and reimbursement nationally.

Scope: Brand-level: Saxenda and Rybelsus only, fee-for-service and managed care, 2025

Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. State coverage rules differ for each product. Compounded products are not included.

Download the data (CSV)

From the public record

Listed patents: Saxenda and Rybelsus

The FDA Orange Book lists 2 patents not yet expired for Saxenda (latest expiry 2037-07-09) and 14 patents for Rybelsus (latest expiry 2034-05-02). Earliest approvals on file are 2014-12-23 and 2019-09-20.

Listed patents: Saxenda and Rybelsus: the figures
MeasureValue
Saxenda: listed patents not yet expired2
Rybelsus: listed patents not yet expired14
Saxenda: latest listed patent expiry2037-07-09
Rybelsus: latest listed patent expiry2034-05-02
Saxenda: earliest approval on file2014-12-23
Rybelsus: earliest approval on file2019-09-20

Source: FDA, Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), data as of Oct 9, 2026

How this was calculated

For each brand, selected its single-ingredient Orange Book products by trade name and counted the distinct unexpired patents listed against them.

Scope: Brand-level: Orange Book products sold under the names Saxenda and Rybelsus only, files dated 2026-10-09

An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.

Download the data (CSV)

At a glance

  • Saxenda / liraglutide 3 mg once-daily injection for weight management in adults with obesity, adults with overweight plus a comorbidity, and patients 12 and older above 60 kg with obesity [5]
  • Rybelsus / oral semaglutide 3, 7 or 14 mg daily for type 2 diabetes and cardiovascular risk reduction; no weight-loss indication [2]
  • Generic liraglutide / FDA-approved, including generics that carry the weight-management label [1]
  • 2018 coverage analysis / 11% of 136 marketplace plans in 34 states had any coverage for the obesity drugs examined; Medicare excluded obesity drug therapy [4]
  • Saxenda checkpoint / label says to assess weight at 16 weeks in adults and stop if less than 4% of baseline is lost [5]
  • Rybelsus start / 3 mg daily for 30 days, a dose the label says is not effective for glycemic control [2]

Which has a generic?

Generic liraglutide is FDA-approved [1]. Generics referencing Saxenda carry the weight-management label (Teva ANDA 214568, Biocon ANDA 217063, Cipla ANDA 217234); generics referencing Victoza carry the type 2 diabetes label, such as Hikma ANDA 215503 [1]. Rybelsus is a Novo Nordisk brand tablet; the Drugs@FDA page for its application (NDA 213051) lists only Rybelsus and Ozempic tablets [3].

Indications and coverage data

Saxenda is indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, adults with overweight plus at least one weight-related comorbidity, and patients aged 12 and older above 60 kg with obesity [5]. Rybelsus is indicated to improve glycemic control in adults with type 2 diabetes and to reduce major adverse cardiovascular events in adults with type 2 diabetes at high risk [2].

In a 2018 analysis of obesity drugs, Medicare policy excluded drug therapy for obesity, and 11% of 136 marketplace plans in 34 states had some coverage for the drugs examined [4]. That analysis predates current plan rules and does not address Rybelsus's type 2 diabetes indication, so it cannot be used to compare current coverage of the two products [2][4].

Questions worth asking

Choose the questions you want to keep

What the labels require

The Saxenda label says to evaluate weight 16 weeks after starting and to discontinue if an adult has not lost at least 4% of baseline body weight [5]. The Rybelsus label starts at 3 mg daily for 30 days, a dose it states is not effective for glycemic control, then 7 mg for days 31 to 60, then 7 or 14 mg from day 61 depending on glycemic need [2].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, which statement about the 3 mg starting dose of Rybelsus is correct?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Frequently asked questions

Does Saxenda have a generic version?
Yes. Generic liraglutide is FDA-approved, including generics that reference Saxenda and carry the weight-management label, such as Teva (ANDA 214568), Biocon (ANDA 217063) and Cipla (ANDA 217234) [1].
Is Rybelsus approved for weight loss?
No. Rybelsus is indicated for glycemic control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk; weight loss is not an approved use [2].
What coverage data exist for these drugs?
Saxenda is approved for weight management [5], while Rybelsus is approved for type 2 diabetes [2]. A 2018 analysis found that Medicare policy excluded drug therapy for obesity and that 11% of 136 marketplace plans in 34 states covered any of the obesity drugs examined [4]. Coverage depends on current plan rules.
Does Rybelsus start at the treatment dose?
No. The label starts at 3 mg daily for 30 days and states that this dose is not effective for glycemic control; it steps to 7 mg for days 31 to 60, then 7 or 14 mg from day 61 [2].

References

Show all 7 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (oral semaglutide) label
  3. Drugs@FDA: FDA-Approved Drugs.
  4. Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018;42(3):495-500.
  5. U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
  6. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
  7. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.
Evidence overview for Saxenda vs Rybelsus: Cost and Access Head-to-Head